Literature DB >> 8723947

Epidermal growth factor receptor (EGF-R) in human middle ear cholesteatoma: an analysis of protein production and gene expression.

J Bujía1, C Kim, A Holly, H Sudhoff, P Ostos, E Kastenbauer.   

Abstract

Previous studies have shown an altered epithelial cell proliferation in middle ear cholesteatoma, reporting an aberrant expression of epidermal growth factor receptor (EGF-R) glycoprotein by immunohistochemistry. In this study, we quantified the presence of EGF-R using enzyme-linked immunosorbent assays (ELISAs) on tissue extracts, as well as the EGF-R gene expression by in situ hybridization on frozen sections. Human skin obtained from the external ear canal was used as control. The amounts of EGF-R glycoprotein in cholesteatoma were very similar to those in human skin. Human skin showed EGF-R messenger RNA (mRNA) only in the basal layer. A higher percentage of cells hybridized for the anti-sense probes EGF-R was found in cholesteatoma epithelium. Furthermore, we could find suprabasal cells with EGF-R mRNA. Our results confirm that the abnormal growth of cholesteatoma epithelium is reflected in an aberrant expression of EGF receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723947

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  9 in total

1.  EGFR expression in acquired middle ear cholesteatoma in children and adults.

Authors:  Adriana Leal Alves; Celina Siqueira Barbosa Pereira; Maria de Fatima Pereira Carvalho; Jose Humberto Tavares Guerreiro Fregnani; Fernando Quintanilha Ribeiro
Journal:  Eur J Pediatr       Date:  2011-07-29       Impact factor: 3.183

2.  Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma.

Authors:  Ela Araz Server; Çiğdem Kalaycık Ertugay; Sevim Baykal Koca; Ecem Sevim Longur; Özgür Yiğit; Hasan Demirhan; Yasemin Çakır
Journal:  J Int Adv Otol       Date:  2019-04       Impact factor: 1.017

Review 3.  Etiopathogenesis of cholesteatoma.

Authors:  Ewa Olszewska; Mathias Wagner; Manuel Bernal-Sprekelsen; Jörg Ebmeyer; Stefan Dazert; Henning Hildmann; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-27       Impact factor: 2.503

4.  Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium.

Authors:  Wei Liu; Tuanfang Yin; Jihao Ren; Lihua Li; Zian Xiao; Xing Chen; Dinghua Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-05       Impact factor: 2.503

5.  Laser-assisted cholesteatoma surgery: technical aspects, in vitro implementation and challenge of selective cell destruction.

Authors:  Philipp P Caffier; Ulrike Marzahn; Andrea Franke; Holger Sudhoff; Sergije Jovanovic; Andreas Haisch; Benedikt Sedlmaier
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-06       Impact factor: 2.503

6.  Expression of EGFR and Microvessel Density in Middle Ear Cholesteatoma.

Authors:  Bong Joon Jin; Hyun Jung Min; Jin Hyeok Jeong; Chul Won Park; Seung Hwan Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-05-31       Impact factor: 3.372

7.  The role of inflammatory mediators in the pathogenesis of otitis media and sequelae.

Authors:  Steven K Juhn; Min-Kyo Jung; Mark D Hoffman; Brian R Drew; Diego A Preciado; Nicholas J Sausen; Timothy T K Jung; Bo Hyung Kim; Sang-Yoo Park; Jizhen Lin; Frank G Ondrey; David R Mains; Tina Huang
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-09-30       Impact factor: 3.372

8.  Comparative analysis of the expression of involucrin, filaggrin and cytokeratin 4, 10, 16 in cholesteatoma.

Authors:  Hyun Jung Min; Chul Won Park; Jin Hyeok Jeong; Seok Hyun Cho; Kyung Rae Kim; Seung Hwan Lee
Journal:  Korean J Audiol       Date:  2012-12-18

9.  Delays in surgery for cholesteatoma due to COVID-19: is there an impact on rates of recidivism and major complications?

Authors:  Mohammed Hassan Hussain; Manish Mair; Sara Mahmood; Georgios Sakagiannis; Djamila M Rojoa; Firas J Raheman; Esmee Irvine; Peter Rea
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-10-10       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.